Balyasny Asset Management’s Definium Therapeutics DFTX Stock Holding History
Bought
Maintained
Sold
Other funds holding DFTX
Balyasny Asset Management's DFTX Position: Q3 2026 in Review
Balyasny Asset Management reduced its Definium Therapeutics (DFTX) stake by 39% in Q3 2026, selling an estimated $14.7M and leaving 549,443 shares worth $20.9M. The position accounts for 0.02% of the portfolio, ranked #755.
Balyasny Asset Management first reported a position in DFTX in Q2 2022 and has held it in 9 quarters since. The position peaked at $42.2M in Q2 2026. 354 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.
- Balyasny Asset Management held 549,443 shares of Definium Therapeutics worth $20.9M as of Q3 2026.
- Balyasny Asset Management sold 348,215 Definium Therapeutics shares in Q3 2026, an estimated $14.7M.
- Definium Therapeutics made up 0.02% of Balyasny Asset Management's portfolio in Q3 2026, its #755 holding.
- Balyasny Asset Management first reported a position in Definium Therapeutics in Q2 2022 and has held it in 9 quarters since.
- Balyasny Asset Management's Definium Therapeutics position peaked at $42.2M in Q2 2026.
- 354 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.
Based on Balyasny Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.